Klaus Höfner

Summary

Country: Germany

Publications

  1. ncbi Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia
    K Hofner
    Urologische Klinik, Ev Krankenhaus Oberhausen, Germany
    World J Urol 19:336-43. 2001
  2. ncbi Alfuzosin: a clinically uroselective alpha1-blocker
    Klaus Höfner
    Evang Krankenhaus Oberhausen, Urologische Klinik, Germany
    World J Urol 19:405-12. 2002
  3. ncbi [Overactive bladder--treatment with antimuscarinic agents]
    K Hofner
    Klinik für Urologie und Kinderurologie, Ev Krankenhaus Oberhausen
    Urologe A 42:793-800. 2003
  4. ncbi Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia
    K Hofner
    Urologische Klinik, Evangelisches Krankenhaus Oberhausen, Virchowstrasse 20, 46047 Oberhausen, Germany
    World J Urol 25:627-33. 2007

Detail Information

Publications6

  1. ncbi Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia
    K Hofner
    Urologische Klinik, Ev Krankenhaus Oberhausen, Germany
    World J Urol 19:336-43. 2001
    ..An overview of the results of 20 clinical trials and post-marketing surveillance studies including more than 10000 patients is presented...
  2. ncbi Alfuzosin: a clinically uroselective alpha1-blocker
    Klaus Höfner
    Evang Krankenhaus Oberhausen, Urologische Klinik, Germany
    World J Urol 19:405-12. 2002
    ..Alfuzosin 10 mg o.d. also exhibits an excellent sexual side-effect profile, with no deleterious impact on this important aspect of quality of life for BPH patients...
  3. ncbi [Overactive bladder--treatment with antimuscarinic agents]
    K Hofner
    Klinik für Urologie und Kinderurologie, Ev Krankenhaus Oberhausen
    Urologe A 42:793-800. 2003
    ..The presented paper gives an overview about the existing data on drugs approved in Germany whose clinical effect has been proven in randomized studies or are have stood the test of time in daily clinical practice...
  4. ncbi Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia
    K Hofner
    Urologische Klinik, Evangelisches Krankenhaus Oberhausen, Virchowstrasse 20, 46047 Oberhausen, Germany
    World J Urol 25:627-33. 2007
    ..5 and OAB-q HRQL scores increased from 59.2 to 81.6. In men with OAB symptoms and presumed non-obstructive BPH, tolterodine ER provided considerable symptomatic and QoL improvements with a low risk of AUR, acute UTI, or increased PVR...